Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
465
mi
from 43215
Verona, NJ
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
465
mi
from 43215
Verona, NJ
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
1670
mi
from 43215
Calgary,
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
1670
mi
from 43215
Calgary,
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
331
mi
from 43215
Washington Park, MD
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
331
mi
from 43215
Washington Park, MD
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
626
mi
from 43215
Saint Joseph, MO
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
626
mi
from 43215
Saint Joseph, MO
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
481
mi
from 43215
New York, NY
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
617
mi
from 43215
Cranston, RI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
617
mi
from 43215
Cranston, RI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
995
mi
from 43215
Houston, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1126
mi
from 43215
San Antonio, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1126
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
697
mi
from 43215
Fort Smith, AR
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
697
mi
from 43215
Fort Smith, AR
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1986
mi
from 43215
Fresno, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1986
mi
from 43215
Fresno, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1961
mi
from 43215
Irvine, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1961
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1983
mi
from 43215
Los Angeles, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1983
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1945
mi
from 43215
Oceanside, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1945
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1960
mi
from 43215
Santa Ana, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1960
mi
from 43215
Santa Ana, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1160
mi
from 43215
Denver, CO
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1160
mi
from 43215
Denver, CO
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from 43215
North Logan, CT
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from 43215
North Logan, CT
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
424
mi
from 43215
Atlanta, GA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
424
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
274
mi
from 43215
Chicago, IL
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from 43215
Dundee, IL
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from 43215
Dundee, IL
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
166
mi
from 43215
Indianapolis, IN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
189
mi
from 43215
New Albany, IN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
189
mi
from 43215
New Albany, IN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
626
mi
from 43215
Overland Park, KA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
626
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
797
mi
from 43215
New Orleans, LA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
797
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
643
mi
from 43215
Andover, MA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
643
mi
from 43215
Andover, MA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
254
mi
from 43215
Bay City, MI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
254
mi
from 43215
Bay City, MI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
629
mi
from 43215
Fridley, MN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
629
mi
from 43215
Fridley, MN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
320
mi
from 43215
High Point, NC
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
320
mi
from 43215
High Point, NC
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
96
mi
from 43215
Cincinnati, OH
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
96
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
350
mi
from 43215
Greer, SC
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
350
mi
from 43215
Greer, SC
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
905
mi
from 43215
Dallas, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
1007
mi
from 43215
Webster, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
1007
mi
from 43215
Webster, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
426
mi
from 43215
Norfolk, VA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
426
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
2007
mi
from 43215
Seattle, WA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from 43215
Surrey,
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from 43215
Surrey,
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
180
mi
from 43215
West Bloomfield Township, MI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
180
mi
from 43215
West Bloomfield Township, MI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
626
mi
from 43215
Saint Joseph, MO
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
626
mi
from 43215
Saint Joseph, MO
Click here to add this to my saved trials
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Status: Enrolling
Updated:  10/24/2017
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Status: Enrolling
Updated: 10/24/2017
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Status: Enrolling
Updated:  10/25/2017
Seton Family of Hospitals- Trinity Clinic
1065
mi
from 43215
Austin, TX
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Status: Enrolling
Updated: 10/25/2017
Seton Family of Hospitals- Trinity Clinic
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
993
mi
from 43215
Miami, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
354
mi
from 43215
Durham, NC
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials